Enclomiphene Citrate Cost in Pennsylvania 2026

What Is Enclomiphene Citrate and Why Does Cost Vary So Much?

Enclomiphene citrate is the trans-isomer of clomiphene. It acts as a selective estrogen receptor modulator at the hypothalamic level, blocking negative feedback and raising endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drives the testes to produce more testosterone. Unlike exogenous testosterone therapy, enclomiphene preserves gonadotropin signaling and, with it, sperm production. Kim et al. (BJU Int, 2016) demonstrated that enclomiphene 12.5 mg and 25 mg daily raised mean serum testosterone from hypogonadal levels (<300 ng/dL) to normal range within four weeks while maintaining sperm counts, compared with a decline in sperm concentration on topical testosterone gel (P<0.001 vs. gel arm at week 16).

Cost variation in Pennsylvania stems from three separate supply chains: branded prescription product dispensed at a retail or specialty pharmacy, compounded versions prepared by a 503A pharmacy under patient-specific prescriptions, and manufacturer patient-assistance programs. Each pathway carries a different price point, a different insurance relationship, and different legal standing under both federal and Pennsylvania state pharmacy law. The FDA's approved drug database lists the current regulatory status of enclomiphene-containing products, which affects which channel a Pennsylvania prescriber may legally use.

Because enclomiphene is prescribed off-label for secondary hypogonadism in most clinical settings today, payers apply inconsistent coverage criteria. That inconsistency is the single biggest driver of the $90-to-$300-per-month price spread Pennsylvania patients report. PubMed data on SERM-based hypogonadism treatment help clinicians justify medical necessity to insurers, but approval is not guaranteed.

Pennsylvania 503A Compounding: The $90/Month Option

The most accessible price point for Pennsylvania patients is a 503A compounded enclomiphene citrate prescription, which runs approximately $90 per month at most licensed compounding pharmacies operating in the state.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits a licensed pharmacist to compound a drug for an individual patient upon receipt of a valid prescription from a licensed practitioner. Pennsylvania's State Board of Pharmacy enforces these rules at the state level. A 503A pharmacy may not compound a drug that is a copy of a commercially available product, but because no FDA-approved enclomiphene-only oral tablet currently appears on the commercial formulary under that exact moniker, compounding pharmacies have historically prepared it. The FDA's compounding guidance page outlines when compounding is permissible, and Pennsylvania patients and prescribers should confirm current FDA status before initiating a compounded prescription because the regulatory environment can shift.

At $90 per month, the compounded route is roughly 30 to 50 percent cheaper than cash-pay retail for comparable doses. A typical prescription is 12.5 mg or 25 mg oral capsules dispensed as a 30-day supply. Some 503A pharmacies offer 90-day supplies at a per-capsule discount, bringing the effective monthly cost to approximately $75 to $80. Research on SERM pharmacology supports doses in this range as clinically effective for raising serum testosterone in men with secondary hypogonadism.

Patients should verify that the pharmacy holds a current Pennsylvania Board of Pharmacy license and, ideally, accreditation from the Pharmacy Compounding Accreditation Board (PCAB). Unaccredited out-of-state compounders shipping into Pennsylvania may not meet state standards and carry additional legal risk for the prescribing clinician.

Cash-Pay Retail Pricing in Pennsylvania

Without insurance or a compounding prescription, Pennsylvania retail pharmacies typically price enclomiphene citrate between $120 and $180 per month for a 30-day supply at standard doses. Prices differ across Philadelphia, Pittsburgh, Allentown, and rural markets because pharmacy reimbursement contracts and local competition vary.

GoodRx, RxSaver, and similar discount platforms can reduce retail cash-pay costs by 20 to 40 percent at major chains including CVS, Rite Aid, and Giant Pharmacy locations across Pennsylvania. Patients should compare coupons at the point of sale rather than assuming any single platform offers the best price. The NIH National Library of Medicine's drug pricing resources note that pharmacy benefit managers negotiate behind-the-scenes discounts that may or may not flow through to cash-pay customers.

One practical note: discount cards and insurance benefits cannot typically be combined. A patient should calculate the total out-of-pocket cost under each scenario before deciding which to use at the pharmacy counter.

Pennsylvania Medicaid Coverage for Enclomiphene Citrate

Pennsylvania Medicaid (Medical Assistance) may cover enclomiphene citrate for secondary hypogonadism when the prescriber documents medical necessity, although coverage is not automatic and requires prior authorization in most managed-care organization (MCO) contracts.

Pennsylvania expanded Medicaid under the Affordable Care Act, and approximately 3.5 million Pennsylvanians are currently enrolled across five managed-care plans contracted with the Department of Human Services. Each MCO maintains its own formulary. Some plans list clomiphene citrate (the racemic mixture) as a covered fertility agent, but enclomiphene citrate as a distinct compound may require a separate prior authorization with diagnosis codes indicating male hypogonadism (ICD-10 E23.0 or E29.1) rather than infertility codes alone.

The Endocrine Society's clinical practice guideline on male hypogonadism states: "We recommend against testosterone therapy in patients who desire fertility in the near term," instead suggesting gonadotropin or SERM-based options. This guideline language is frequently cited in prior authorization appeals because it establishes clinical rationale for choosing enclomiphene over testosterone replacement in Medicaid-enrolled men who want to preserve fertility.

Prior authorization denials can be appealed. A successful appeal typically requires a serum testosterone level below 300 ng/dL on two morning draws taken on separate days, a diagnosis of secondary (hypogonadotropic) hypogonadism confirmed by low or normal LH and FSH in the context of low testosterone, and a prescriber letter referencing peer-reviewed evidence. Kim et al. (BJU Int, 2016) is directly citable in that letter.

Private Insurance Coverage in Pennsylvania

Private insurers operating in Pennsylvania, including Independence Blue Cross, Highmark, UPMC Health Plan, Aetna, Cigna, and UnitedHealthcare, do not uniformly cover enclomiphene citrate. Coverage depends on the specific plan tier, the diagnosis code submitted, and whether the drug appears on the plan's formulary as a branded or compounded product.

Testosterone-related medications are sometimes excluded from employer-sponsored health plans under provisions targeting "lifestyle" drugs, a categorization that clinicians dispute given that secondary hypogonadism is a diagnosable endocrine condition. The NIH's MedlinePlus resource on hypogonadism classifies it as a medical condition, not a lifestyle choice, which supports appeals language.

When a plan does cover enclomiphene, it typically lands on Tier 2 or Tier 3, with copays ranging from $40 to $90 per month after deductible. Specialty pharmacy requirements may apply. Patients should call the member services number on the back of their insurance card and ask specifically whether the plan covers "enclomiphene citrate" (not clomiphene) under the male hypogonadism indication before assuming their plan includes it.

The American Urological Association's guidance on evaluation and management of testosterone deficiency provides additional clinical backing for medical necessity documentation, noting that SERM therapy is an appropriate alternative to exogenous testosterone in selected patients.

Telehealth Prescribing of Enclomiphene in Pennsylvania

Pennsylvania permits telehealth prescribing of controlled substances and non-controlled medications under rules codified in Act 96 of 2020 and subsequent Pennsylvania Department of State guidance. Enclomiphene citrate is not a controlled substance, so the prescribing requirements are less restrictive than for, say, testosterone cypionate.

A Pennsylvania-licensed physician or advanced practice provider may evaluate a patient via synchronous video visit, order laboratory tests (serum testosterone, LH, FSH, complete blood count, metabolic panel), review results, and prescribe enclomiphene citrate without an in-person encounter. The prescription can then be sent electronically to a 503A compounding pharmacy or a retail pharmacy licensed in Pennsylvania.

Telehealth platforms offering this service typically charge a monthly membership or consultation fee ranging from $50 to $150 on top of medication costs. When the compounded medication runs $90 per month and the telehealth platform fee is $75, total monthly spend is roughly $165, which remains below average retail cash-pay for the medication alone at many Pennsylvania pharmacies.

The American Telemedicine Association's standards and Pennsylvania's telehealth statute both require that a valid prescriber-patient relationship be established before any medication is prescribed. Patients should confirm that the telehealth provider is licensed in Pennsylvania and that lab work is ordered through a CLIA-certified laboratory before the first prescription is issued. The CDC's CLIA overview explains laboratory certification requirements relevant to this step.

How Lab Costs Factor Into Total Enclomiphene Spend in Pennsylvania

The medication price is only one component of total treatment cost. Patients starting enclomiphene citrate require baseline and monitoring labs, and in Pennsylvania these carry real out-of-pocket costs unless insurance covers laboratory benefits.

A baseline panel typically includes serum total testosterone (two morning draws), free testosterone, LH, FSH, prolactin, complete blood count, and comprehensive metabolic panel. At Quest Diagnostics or LabCorp locations across Pennsylvania, this panel costs between $150 and $280 without insurance. Follow-up testosterone and LH draws at four to six weeks cost approximately $60 to $120 per visit.

The Endocrine Society's guideline on biochemical testing for hypogonadism recommends confirming two low morning testosterone readings before initiating therapy. That recommendation means most patients face two separate lab draws before receiving a prescription, adding $120 to $200 to first-month costs even before the medication is purchased.

Patients with private insurance that includes lab benefits can reduce these costs substantially. Pennsylvania Medicaid covers medically necessary laboratory services with no copay for most enrolled members, so Medicaid patients face lower total first-month costs than cash-pay patients. The NIH's guidance on laboratory reference ranges for testosterone provides the clinical context for interpreting these results.

Total Annual Cost Scenarios for a Pennsylvania Patient in 2026

Breaking costs down by payment pathway gives Pennsylvania patients a realistic picture of annual spend.

Scenario A: Compounded 503A, cash-pay labs, no insurance. Medication at $90/month equals $1,080/year. Baseline labs cost approximately $200. Quarterly follow-up labs at $80 each add $320. Total annual cost: roughly $1,600.

Scenario B: Retail pharmacy with GoodRx discount. Medication at $130/month (post-discount) equals $1,560/year. Same lab costs as above. Total annual cost: roughly $2,080.

Scenario C: Pennsylvania Medicaid covering medication and labs. Patient copay is $0 to $3 per prescription and $0 for covered labs. Total annual cost: approximately $36 to $72 in prescription copays if a $3 copay per fill applies.

Scenario D: Private insurance, Tier 3 copay. Monthly copay of $65 equals $780/year for medication. Labs may be covered at 80 percent after deductible. If deductible is met, total annual cost: roughly $900 to $1,200 depending on plan year dynamics.

Research on long-term SERM therapy outcomes suggests most men see significant testosterone improvement within four to six weeks, but clinical benefit often warrants continuation beyond three months, making annual cost projections more relevant than single-month quotes.

Manufacturer and Pharmacy Discount Programs Available to Pennsylvania Residents

Several cost-reduction programs apply specifically to Pennsylvania patients.

GoodRx and RxSaver discount cards work at most major Pennsylvania retail chains and do not require enrollment. Patients print or display a coupon at the pharmacy counter. These cards are free and may reduce a $160 retail price to approximately $95 to $120 depending on the pharmacy.

Manufacturer patient assistance programs (PAPs) vary by product. Patients should contact the manufacturer of the specific branded product prescribed to ask about PAPs for income-qualifying individuals. Eligibility typically requires household income at or below 400 percent of the federal poverty level and lack of adequate insurance coverage.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used to pay for enclomiphene citrate and associated labs tax-free. Pennsylvania does not impose state income tax on HSA distributions used for qualified medical expenses, consistent with federal rules under IRS Publication 969. A patient in the 22 percent federal bracket saving $2,000 annually through an HSA effectively reduces after-tax medication cost by approximately $440.

Telehealth bundled pricing from some platforms includes the consultation, lab orders, and medication at a single monthly rate, sometimes as low as $150 to $200 all-in for the first month. Patients should read the fine print to confirm whether labs and shipping are included or billed separately. FDA consumer guidance on prescription drug pricing advises consumers to compare total costs rather than medication sticker price alone.

Compounded Enclomiphene Legality in Pennsylvania: What Patients Need to Know

Compounded enclomiphene citrate is legal in Pennsylvania when prepared by a 503A-licensed pharmacy under a valid patient-specific prescription from a licensed Pennsylvania prescriber.

The key legal constraints are: the pharmacy must hold a current Pennsylvania Board of Pharmacy license; the compound must not be a copy of a commercially available FDA-approved product in the same strength and dose form; the prescription must be individualized (not manufactured in bulk for office use); and the drug substance used as the active pharmaceutical ingredient must be sourced from an FDA-registered facility.

The FDA's 503A compounding framework sets the federal floor, and Pennsylvania's pharmacy regulations at 49 Pa. Code Chapter 27 set additional state requirements. A prescriber who refers patients to an out-of-state 503A compounder not licensed in Pennsylvania may be exposing both the patient and themselves to legal risk.

The USP standards for compounded preparations (USP chapters 795 and 797) apply to compounding pharmacies and govern sterility, beyond-use dating, and quality controls. Oral capsules like compounded enclomiphene fall under USP 795. Patients can ask the pharmacy directly whether it follows current USP 795 standards as a quality checkpoint.

Buying enclomiphene from an international online pharmacy without a valid prescription is illegal under the Federal Food, Drug, and Cosmetic Act and Pennsylvania law, and the product received may be adulterated or mislabeled. The FDA's guidance on importing drugs addresses this clearly.

Clinical Monitoring Pennsylvania Prescribers Require Before and During Treatment

Knowing what lab monitoring will be required helps patients budget accurately and avoid surprise costs.

Before prescribing, most Pennsylvania clinicians following the Endocrine Society's 2018 clinical practice guidelines require two fasting morning serum testosterone draws on separate days, both below 300 ng/dL, with LH and FSH confirming the secondary (central) origin of the low testosterone. Prolactin and iron studies are ordered if a pituitary cause is suspected.

After four to six weeks of enclomiphene at 12.5 mg or 25 mg daily, repeat serum testosterone and LH confirm the drug is working. Kim et al. reported mean testosterone rising from approximately 230 ng/dL at baseline to 430 ng/dL at four weeks on the 12.5 mg dose (P<0.001 vs. placebo), demonstrating that early monitoring is both clinically informative and reflects real therapeutic response rather than placebo effect.

Long-term monitoring (every three to six months) typically includes testosterone, LH, FSH, and hematocrit. The American Society of Reproductive Medicine's guidance on male reproductive health recommends semen analysis every six months in men using SERM therapy who are being evaluated for fertility, adding an additional $80 to $150 per analysis to annual monitoring costs at most Pennsylvania andrology labs.

Why Enclomiphene May Be Preferred Over Clomiphene in Pennsylvania Prescribing

Clinicians in Pennsylvania who are familiar with both agents increasingly prefer enclomiphene for male hypogonadism because the zuclomiphene isomer (present in racemic clomiphene) has estrogenic properties that can cause mood changes, visual disturbances, and gynecomastia in some men.

Taylor et al. (Int J Impot Res, 2023, via PubMed) analyzed SERM tolerability in men with secondary hypogonadism and found a statistically lower rate of estrogen-related adverse effects with enclomiphene than with racemic clomiphene at comparable testosterone-raising doses. The absence of the zuclomiphene isomer means patients are less likely to require adjunct aromatase inhibitor therapy, which would add another $40 to $90 per month to total treatment costs in Pennsylvania.

That pharmacological distinction also matters for insurance coverage. Some Pennsylvania insurance plans have clomiphene listed as a covered fertility agent (for female indication), but enclomiphene is a distinct drug entity. A prescriber writing "enclomiphene citrate" rather than "clomiphene citrate" may trigger a non-formulary review, so prior authorization paperwork should specify the clinical rationale for the isomer-specific selection. The FDA drug label database can be used to verify the exact drug name on file with the agency for coding purposes.

HealthRX Perspective on Navigating Pennsylvania Enclomiphene Costs

Across patients receiving care through telehealth providers operating in Pennsylvania, the most cost-effective pathway for most men without Medicaid is the compounded 503A route combined with an HSA for lab payments, bringing total annual spend to approximately $1,400 to $1,700. Men with Pennsylvania Medicaid who meet prior authorization criteria face the lowest total costs. Private insurance coverage is inconsistent but worth pursuing through a formal prior authorization, particularly for patients on Highmark or UPMC Health Plan, which have recently updated their male hypogonadism prior authorization criteria to align more closely with Endocrine Society guideline language.

Patients should bring to their first telehealth or in-person visit: two prior testosterone lab results if available, a list of current medications including any supplements, and documentation of symptoms consistent with hypogonadism (fatigue, reduced libido, decreased morning erections, mood changes). This preparation reduces the number of initial visits required and directly lowers cost.